http://idea.sec.gov/Archives/edgar/d...73936z0016.gif


4 out of the 5 patients who developed PML are alive. They will update on the patients at a scientific conference.

They are working to identify new methods of risk assessment. In the Q & A they hoped to be testing these methods by mid-2009.

Other items I note

4 out of the 5 PML cases have occurred in European patients. The US TOUCH program would seem to offer PML risk reduction.

4 of the 5 cases occurred between 12 and 17 months of treatment. The risk of PML would appear to not increase with increasing time on drug - only 1 case in patients with over 2 years of exposure.